By ANMAT regulation DI-2023-5343-APN-ANMAT#MS of July 18, 2023, the results of the Bioequivalence Study designed, carried out and analyzed by FP CLINICAL PHARMA were accepted. This allowed us to declare the Bioequivalence of the DROPICINE® product? vs. RISPERDAL® from JanssenCilag Farmacéutica S.A. One more step towards better access to Medicines with Proven Quality for the Health of Argentines ANMAT Salud.

The National Administration of Drugs, Food and Medical Technology has renewed the Authorization of FP Clinical Pharma S.R.L. to carry out PHASE IV CLINICAL PHARMACOLOGY STUDIES OF BIOEQUIVALENCE IN ADULT POPULATION.